Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
UNC Lineberger Comprehensive Cancer Center
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03721068CT.gov Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neuroblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ic9.gd2.car.il-15 t-cells (this asset) | UNC Lineberger Comprehensive Cancer Center | P1 | CC · 41 |
| Etoposide | M.D. Anderson Cancer Center | P2/3 | BB |
| Nivestim | M.D. Anderson Cancer Center | P4 | BB |
| Cyclophosphamide | Robbie Majzner | P2 | BB |
| Carboplatin | St. Jude Children's Research Hospital | P2/3 | BB |
| Gm-Csf | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | P4 | BB |
| Melphalan | M.D. Anderson Cancer Center | P2/3 | BB |
| Nogitecan | Novartis Pharmaceuticals | P2 | BB |
| Adriamycin | Hoffmann-La Roche | P2 | BB |
+42 more in the Neuroblastoma cohort
Other indications for ic9.gd2.car.il-15 t-cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteosarcoma | — | P1 | CC · 41 |
| Small Cell Lung Carcinoma | — | Early P1 | C · 38 |
| Lung Cancer | — | Early P1 | C · 34 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ic9.gd2.car.il-15 t-cells in Neuroblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ic9gd2caril-15-t-cells-neuroblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →